Published in J Biol Chem on August 18, 2005
NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest (2008) 2.29
NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol (2007) 2.25
Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood (2005) 1.38
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum (2008) 1.36
Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.25
Regulation of NFATc1 in Osteoclast Differentiation. J Bone Metab (2014) 1.15
Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr (2009) 1.11
Osteoclast fusion and regulation by RANKL-dependent and independent factors. World J Orthop (2012) 1.11
Transcriptional regulation of bone and joint remodeling by NFAT. Immunol Rev (2010) 1.06
Gene disruption of the calcium channel Orai1 results in inhibition of osteoclast and osteoblast differentiation and impairs skeletal development. Lab Invest (2012) 1.04
The role of calcium release activated calcium channels in osteoclast differentiation. J Cell Physiol (2011) 0.98
Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1. FASEB J (2011) 0.96
Myocyte enhancer factor 2 and microphthalmia-associated transcription factor cooperate with NFATc1 to transactivate the V-ATPase d2 promoter during RANKL-induced osteoclastogenesis. J Biol Chem (2009) 0.96
TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PLoS One (2011) 0.95
Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol (2006) 0.95
Signaling Pathways in Osteoclast Differentiation. Chonnam Med J (2016) 0.94
Plasma membrane calcium ATPase regulates bone mass by fine-tuning osteoclast differentiation and survival. J Cell Biol (2012) 0.93
Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation. J Biol Chem (2009) 0.92
Negative feedback control of osteoclast formation through ubiquitin-mediated down-regulation of NFATc1. J Biol Chem (2009) 0.91
Osteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss. J Immunol Res (2015) 0.89
The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther (2012) 0.88
Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts. World J Orthop (2012) 0.86
Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients. Arthritis Res Ther (2007) 0.85
Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass. J Bone Miner Res (2013) 0.85
Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis. Cell Res (2013) 0.85
Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis. PLoS One (2009) 0.84
Inhibitory effect of luteolin on osteoclast differentiation and function. Cytotechnology (2010) 0.83
2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes. Br J Pharmacol (2010) 0.83
MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis. Int J Mol Sci (2016) 0.81
Regulators of G protein signaling 12 promotes osteoclastogenesis in bone remodeling and pathological bone loss. Cell Death Differ (2015) 0.81
SLAT negatively regulates RANKL-induced osteoclast differentiation. Mol Cells (2013) 0.81
The transmembrane adaptor protein, linker for activation of T cells (LAT), regulates RANKL-induced osteoclast differentiation. Mol Cells (2012) 0.80
Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism. J Biol Chem (2011) 0.80
(+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation. PLoS One (2014) 0.80
NRROS Negatively Regulates Osteoclast Differentiation by Inhibiting RANKL-Mediated NF-N:B and Reactive Oxygen Species Pathways. Mol Cells (2015) 0.78
Pyrroloquinoline quinine inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos in mouse bone marrow cells and inhibits wear particle-induced osteolysis in mice. PLoS One (2013) 0.78
A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol (2012) 0.78
Lhx2 regulates bone remodeling in mice by modulating RANKL signaling in osteoclasts. Cell Death Differ (2014) 0.78
STAT5 is a key transcription factor for IL-3-mediated inhibition of RANKL-induced osteoclastogenesis. Sci Rep (2016) 0.77
Negative autoregulation of RANKL and c-Src signaling in osteoclasts. J Bone Miner Metab (2007) 0.77
Selective induction of P2Y14 receptor by RANKL promotes osteoclast formation. Mol Cells (2013) 0.76
Attenuation of RANKL-induced Osteoclast Formation via p38-mediated NFATc1 Signaling Pathways by Extract of Euphorbia Lathyris L. J Bone Metab (2016) 0.75
The Influence of DNA Methylation on Bone Cells. Curr Genomics (2015) 0.75
Sirt6 cooperates with Blimp1 to positively regulate osteoclast differentiation. Sci Rep (2016) 0.75
Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells. BMC Complement Altern Med (2014) 0.75
Mitf regulates osteoclastogenesis by modulating NFATc1 activity. Exp Cell Res (2014) 0.75
Wogonin inhibits osteoclast differentiation by inhibiting NFATc1 translocation into the nucleus. Exp Ther Med (2015) 0.75
NADPH oxidase gp91(phox) contributes to RANKL-induced osteoclast differentiation by upregulating NFATc1. Sci Rep (2016) 0.75
GATA4 negatively regulates bone sialoprotein expression in osteoblasts. BMB Rep (2016) 0.75
RCANs regulate the convergent roles of NFATc1 in bone homeostasis. Sci Rep (2016) 0.75
Tusc2/Fus1 regulates osteoclast differentiation through NF-κB and NFATc1. BMB Rep (2017) 0.75
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat Immunol (2003) 8.23
Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 8.09
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol (2007) 5.24
Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell (2007) 4.75
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med (2006) 4.60
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature (2011) 4.16
Distinct molecular mechanism for initiating TRAF6 signalling. Nature (2002) 3.82
v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med (2006) 3.78
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Melanocyte biology and skin pigmentation. Nature (2007) 3.43
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol (2006) 3.18
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science (2004) 3.12
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood (2005) 2.95
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell (2004) 2.80
Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol (2004) 2.79
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood (2007) 2.65
Medullary thymic epithelial cells expressing Aire represent a unique lineage derived from cells expressing claudin. Nat Immunol (2007) 2.61
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Hop is an unusual homeobox gene that modulates cardiac development. Cell (2002) 2.52
Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol (2010) 2.47
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A (2010) 2.45
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med (2006) 2.44
Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation (2005) 2.44
TRAF6 is a critical factor for dendritic cell maturation and development. Immunity (2003) 2.36
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity (2002) 2.31
NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol (2007) 2.25
Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med (2005) 2.21
Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity (2002) 2.20
Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene (2003) 2.19
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature (2006) 2.09
Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell (2010) 2.06
A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med (2002) 2.04
The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity (2006) 2.04
Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol (2002) 2.00
Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol (2008) 1.96
An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94
Homeobox protein Hop functions in the adult cardiac conduction system. Circ Res (2005) 1.93
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res (2007) 1.93
MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol (2003) 1.90
Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell (2010) 1.86
TRAF6 autoubiquitination-independent activation of the NFkappaB and MAPK pathways in response to IL-1 and RANKL. PLoS One (2008) 1.86
Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol (2002) 1.82
Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med (2009) 1.81
NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol Cell (2002) 1.79
UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res (2008) 1.78
A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol (2002) 1.74
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A (2003) 1.73
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med (2002) 1.69
Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res (2004) 1.64
Vibrio vulnificus RTX toxin kills host cells only after contact of the bacteria with host cells. Cell Microbiol (2007) 1.64
Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun (2011) 1.62
Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev (2010) 1.61
MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood (2006) 1.60
Transdifferentiation of the retina into pigmented cells in ocular retardation mice defines a new function of the homeodomain gene Chx10. Development (2004) 1.58
Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest (2013) 1.57
Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol (2005) 1.54
GITR Blockade Facilitates Treg Mediated Allograft Survival. Transplantation (2009) 1.48
Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol (2011) 1.47
Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A (2003) 1.46
OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol (2012) 1.43
c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem (2006) 1.42
Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell (2006) 1.41
Sumoylation of MITF and its related family members TFE3 and TFEB. J Biol Chem (2004) 1.40
Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood (2005) 1.38